Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients
- 1 December 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Hematology
- Vol. 6 (6), 767-784
- https://doi.org/10.1586/17474086.2013.858018
Abstract
With a median age at diagnosis of approximately 65-70 years, acute myeloid leukemia (AML) represents a major therapeutic challenge in the elderly. Only 30-35% of elderly patients with AML are considered eligible for intensive chemotherapy and do actually receive it. However, the long-term benefit associated with intensive chemotherapy remains marginal, and the overall outcome for this population remains poor. The remaining 60-65% of elderly AML patients receives supportive care only. Nevertheless, several studies have indicated that patients who receive any therapy had a better outcome if compared with patients who receive supportive care only. Thus, the development of novel, less toxic, targeted agents is offering new options to older AML patients who are unfit for intensive approaches. In the present review, we will report on the results achieved using intensive chemotherapy and novel agents, and will describe some of the new strategies under development for treating older AML patients.Keywords
This publication has 91 references indexed in Scilit:
- TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTSMediterranean Journal of Hematology and Infectious Diseases, 2013
- Acute myeloid leukemia in the real world: why population-based registries are neededBlood, 2012
- A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemiaBlood, 2011
- Dose Escalation of Lenalidomide in Relapsed or Refractory Acute LeukemiasJournal of Clinical Oncology, 2010
- Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999Blood, 2010
- Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced AgeTransplantation and Cellular Therapy, 2010
- Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia GenomeThe New England Journal of Medicine, 2009
- Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related DonorTransplantation and Cellular Therapy, 2008
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987